Prostate cancer is a leading cause of death in men worldwide. For over 30 years, growing
interest has focused on the development of vaccines as treatments for prostate cancer, with …

Prostate cancer is the second most common cause of cancer‐related death in men in the
United States and the fifth worldwide. Most prostate cancer arises as an androgen …

Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) have limited
treatment options after progressing on hormonal therapy and chemotherapy. Here, we …

Prostate cancer is one of the most common malignant tumors in men. Initially, it is androgen-
dependent, but it eventually develops into castration-resistant prostate cancer (CRPC) …

Prostate cancer (PCa) is one of the most prominent causes of cancer‑related mortality in the
male population. A highly impactful prognostic factor for patients diagnosed with PCa is the …

Prostate cancer (PC) is the most common type of tumor in men. In the early stage of the
disease, it is sensitive to androgen deprivation therapy. In patients with metastatic castration …

Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell
engagers, have fundamentally changed our approach to treating cancer. However …

Immunotherapy has shown promising therapeutic effects in hematological malignancies and
certain solid tumors and has emerged as a critical and highly potential treatment modality for …

Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of
cancer treatments. Basic, translational, and clinical research are now investigating …

Data collected from large-scale studies has shown that the incidence of prostate cancer
globally is on the rise, which could be attributed to an overall increase in lifespan. So, the …